Treatment of deep-seated facial microcystic lymphatic malformations with intralesional injection of pingyangmycin

Abstract

Treatment of microcystic lymphatic malformations (LMs) is still a great challenge to physicians in the field of managing vascular anomalies. Several kinds of treatment have been proposed for microcystic LMs, but the responses to these treatment modalities vary considerably among individuals. The aim of the study was to investigate the safety and efficacy of intralesional injection of pingyangmycin for microcystic LMs located in the deep facial region.Twenty-one consecutive patients with deep-seated facial microcystic LMs were treated with intralesional injection of pingyangmycin between March 2010 and April 2015. The patients received 2 to 8 injections, and the average session was 3.7. The therapeutic efficacy was accessed on the basis of the imaging findings and clinical measurements.Among the 21 patients, the clinical responses were excellent in 7 patients (33.33%), good in 9 patients (42.86%), fair in 3 patients (14.29%), and poor in 2 patients (9.52%). No severe side effects were encountered. Furthermore, therapeutic outcomes were significantly associated with lesion location (P = 0.006) and number of injections (P = 0.003).Our study supports that sclerotherapy with pingyangmycin is safe and effective for the treatment of deep-seated facial microcystic LMs.

An Acute Inflammation with Special Expression of CD11 & CD4 Produces Abscopal Effect by Intramoral Injection Chemotherapy Drug with Hapten in Animal Model

“…Comparison with the weight and tumor volume of mice, it was found that weight is stable for control group, a smaller light weight in PYM+DNP treatment group while tumor volume keeps smaller than the control group, that is good signs for control tumor growth. PYM is a clinically anticancer drug which is used for certain cancer patients [17][18][19][20] , also used for local injection in the past. Today, it is first time for intratumoral injection of PYM with DNP, it may not change the function of PYM, but it may let the PYM to play an important role with DNP separately.…”

Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation

“…13 However, sclerotherapy may contribute to the buildup of scar tissue and may allow LM recurrence and regrowth. 11 Sclerotherapy, particularly using bleomycin 12 or pingyangmycin, 14 has been utilized to treat microcystic lymphatic disease, which rarely is surgically excisable given the infiltrative pattern of LM. In our experience, results from individual procedures are modest, whereas sequential sclerotherapy procedures can provide benefit but require serial anesthesia and acceptance of sclerosant risks.…”

Bleomycin for Head and Neck Venolymphatic Malformations: A Systematic Review

“…It is considered that microcystic lymphangiomas tend to be more resistant to treatment than macrocystic lymphangiomas possibly because there are no obvious cysts to target within the lesion. 46 The therapeutic effect on large diffuse lesions was poor. 46…”